Gossamer Bio
Gossamer Bio53
About
What does Gossamer Bio do?
Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing its investigational drug product, seralutinib, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib is an inhaled inhibitor designed to enhance the lives of people living with these rare diseases. The company is committed to advancing new therapies and supporting patient communities. (formerly [].)
What is Gossamer Bio's revenue?
StartupHub estimates Gossamer Bio's annual revenue at $14.8M (range $8.5M to $48.1M, 68% confidence), based on comparable companies in the sector.
What is Gossamer Bio's valuation?
StartupHub estimates Gossamer Bio's effective valuation at $558.3M (range $390.8M to $725.7M, 28% confidence), based on comparable companies in the sector.
How much funding has Gossamer Bio raised?
Gossamer Bio has raised a total of $150M in funding. The most recent round on record is Series B.
Where is Gossamer Bio headquartered?
Gossamer Bio is headquartered in San Diego, California, USA.
When was Gossamer Bio founded?
Gossamer Bio was founded in 2017.
What industry does Gossamer Bio operate in?
Gossamer Bio operates in Biotechnology, Pharmaceuticals, Healthcare, Biotech, MedTech, Drug Discovery.
How many employees does Gossamer Bio have?
Gossamer Bio has approximately 154 people on record.
No comments yet. Be the first to share your take.